/
Gastroenterology
Gastroesophageal Reflux Disease
18
Pipeline Programs↗
21
Active Trials↗
24
Companies Involved↗
Gastroesophageal Reflux Disease is an emerging landscape with 18 programs across 24 companies. The most active players are Takeda, Onconic Therapeutics Inc.. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 1
No programs
Phase 35
Approved
No programs
Analysis
Trial Status
126
clinical trials
Completed92 · 73%
Not yet recruiting12 · 10%
Recruiting8 · 6%
Unknown status8 · 6%
Terminated3 · 2%
Withdrawn2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
126 trials
Effects of an Online Mindfulness-Based Emotion Intervention on Symptoms and Emotional Distress in Patients With Gastroesophageal Reflux Disease: A Multicenter Randomized Waitlist-Controlled Trial
Recruiting·—·Preclinical·NCT07667894·500 enrolled
Effect of Baclofen in Management of Patients With Gastroesophageal Reflux Disease Symptoms
Recruiting·—·Phase 2/3·NCT07063576·60 enrolled
Effect of the Use of Alginate Combined With Licorice and Blueberry in the Symptomatic Treatment of Adult Patients With Gastroesophageal Reflux Disease
Not yet recruiting·LLiaquat University of Medical & Health Sciences·Preclinical·NCT07790549·140 enrolled
Page 1 of 9
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)